Day: August 14, 2020

Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy ProgramConference Call and Webcast Today at 8:30 a.m. ETMALVERN, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to cure blindness diseases, today reported second quarter 2020 financial results along with a general business update.“I am very proud of the progress we have made this quarter as we work to develop transformative therapies with the potential to cure blindness diseases. Despite the challenges of the global pandemic, we remain on track to enter the clinic next year with our first gene therapy product candidate, OCU400, for retinitis pigmentosa. Our second gene therapy product, OCU410, for dry age-related macular degeneration...

 Daron Evans to Remain Senior Science Advisor and CEO of Specialty Renal ProductsSOUTH ORANGE, NJ, Aug. 14, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells water purification products and pathogen detection systems to the medical and commercial markets, today announced that Andy Astor, currently the company’s Chief Operating Officer and Chief Financial Officer, has been named President and CEO, effective August 24, 2020. Mr. Astor was also elected to Nephros’s board of directors.Daron Evans, Nephros’s current President and CEO, will remain with the company as a special advisor focused on the pathogen detection and dialysis businesses. Mr. Evans will also continue as CEO of Specialty Renal Products (“SRP”), a Nephros subsidiary. As part of the transition,...

RUTHERFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced yesterday financial and operating results for the quarter ended June 30, 2020.SECOND QUARTER 2020 FINANCIAL RESULTSThe Company reported total revenue from continuing operations of $1.4 million for the second quarter of 2020 compared to revenue of $1.5 million in the second quarter of 2019, a decrease of approximately $0.1 million or 5% principally due to the timing of discovery services studies.Gross profit remained approximately the same in both of the comparable quarters of 2019 and 2020, while the overall gross margin increased by 4 percentage points, from approximately 52% to 56%. The Discovery Services business unit gross margin increased...

CELEBRATION, Fla., Aug. 14, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company participated in a mid-cycle communication meeting on August 13, 2020, with the U.S. Food and Drug Administration (FDA) regarding the ongoing review of the New Drug Application (NDA) for KP415, KemPharm’s investigational product candidate for the treatment of attention deficit hyperactivity disorder (ADHD).  The FDA did not raise any substantive issues at the meeting and indicated that no major safety concerns have been noted at this point in their review.  Additionally, the PDUFA date of March 2, 2021, was re-affirmed. The FDA also tentatively scheduled a late-cycle communication meeting to be held on December 1, 2020,...

Exebacase Phase 2 study results published in the Journal of Clinical InvestigationContinued patient enrollment in ongoing Phase 3 DISRUPT study of exebacaseSuccessful public equity offering, private placement with Pfizer Inc., and CARB-X grant provide significant funding to advance lead product candidatesYONKERS, New York, Aug. 14, 2020 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the second quarter ended June 30, 2020.“We continued to advance the Phase 3 DISRUPT superiority study of our FDA designated Breakthrough...

VANCOUVER, British Columbia, Aug. 14, 2020 (GLOBE NEWSWIRE) — Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) has reported financial and operating results for the second quarter ended June 30, 2020.This news release should be read in conjunction with Lithium Americas’ unaudited condensed consolidated interim financial statements and management’s discussion and analysis (“MD&A”) for the six months ended June 30, 2020, which are available on the Company’s website and SEDAR.  All amounts are in U.S. dollars unless otherwise indicated.“We remain focused on protecting our workers and communities, while coordinating closely with the Province of Jujuy to ensure we operate responsibly and safely as we begin to restart construction activities over the next few weeks,”...

IH 140647 – Boð á fund skuldabréfaeigandaFundarboð14. ágúst 2020Með vísan til ákvæða skuldabréfsins IH 140647 („skuldabréfið“) boða Íslandshótel ( „útgefandi“) til fundar eigenda skuldabréfsins sem haldinn verður klukkan 13:00 þann 28. ágúst 2020 í fundarherberginu Útgarði á Hótel Grand, Sigtúni 28, 105 Reykjavík.Dagskrá fundarins:Tillaga í tveimur liðum um breytingu á skilmálum skuldabréfsins, þ.e.:Breytingar á greiðsluferli skuldabréfsins og gjalddögum vaxta og afborgana; ogBreytingar á skilmálum skuldabréfanna um sérstök skilyrði, nánar tiltekið um fjárhagslega skilmála.Meðfylgjandi fundarboði þessu er tillaga útgefanda sem tekin verður fyrir sem og umboðseyðublað.Skráning fundargesta og afhending fundargagna verður á fundarstað frá klukkan 12:30 á fundardegi. Þeim fundargestum sem þess óska verður boðið upp á að taka þátt í fundinum...

NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) — August 14, 2020, SCWorx Corp. (Nasdaq: WORX) announced today the appointment of Timothy Hannibal as President, Chief Operating Officer and Director.  Mr. Hannibal, currently the Company’s Chief Revenue Officer and Interim CFO, will report to the Board of Directors and be responsible for overseeing the day to day operations of the Company, including financial operations.Mr. Hannibal is a seasoned technology executive and entrepreneur, with nearly 30 years’ experience in SaaS and cloud technology, driving revenue, go-to-market strategies, business development and mergers and acquisitions. Mr. Hannibal joined the Company in January 2019 and has since served as its Chief Revenue Officer and Interim CFO. Prior to joining the Company, Mr. Hannibal was an executive at Primrose Solutions (the predecessor...

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan”) (TSX: REI.UN) today announced a distribution of 12 cents per unit for the month of August. The distribution will be payable on September 8, 2020 to unitholders of record as at August 31, 2020.About RioCanRioCan is one of Canada’s largest real estate investment trusts. RioCan owns, manages and develops retail-focused, increasingly mixed-use properties located in prime, high-density transit-oriented areas where Canadians want to shop, live and work. As at June 30, 2020, our portfolio is comprised of 221 properties with an aggregate net leasable area of approximately 38.6 million square feet (at RioCan’s interest) including office, residential rental and 15 development properties. To learn more about us, please visit www.riocan.com.Information...

HOUSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2020 and provided an update on recent corporate developments.“Despite the challenges from the COVID-19 pandemic, we were able to continue to make significant progress across our clinical development pipeline. Most importantly, as recently announced, we dosed the first patient in Stage 2 of our Phase 2 trial of prexigebersen as a combination treatment for patients suffering with acute myeloid leukemia (AML),” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We believe that this...